Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 931-096-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
negative, in vitro bacterial reverse mutation (with and without S-9 activation), OECD TG 471, 2016
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline study performed under GLP. All relevant validity criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- inspected June 2015; signature: September 2015
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- E. coli WP2 uvr A
- Additional strain / cell type characteristics:
- not applicable
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver S9
- Test concentrations with justification for top dose:
- Experiment 1 (plate incorporation method): 0, 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plateExperiment 2 (pre-incubation method): 0, 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plateUp to eight test item dose levels were selected in Experiment 2 in order to achieve both a minimum of four non-toxic doses and the toxic/guideline limit of the test item following the change in test methodology.
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: dimethyl sulphoxide (DMSO)- Justification for choice of solvent/vehicle: The test item was immiscible in sterile distilled water at 50 mg/mL but was fully miscible in dimethyl sulphoxide at the same concentration in solubility checks performed. Dimethyl sulphoxide was selected as the vehicle.- Other: Formulated concentrations were adjusted by an appropriate factor to allow for the stated purity of the test substance.
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- N-ethyl-N-nitro-N-nitrosoguanidine
- benzo(a)pyrene
- other: 2-Aminoanthracene
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: Experiment 1. in medium; in agar (plate incorporation) ; Experiment 2. in medium; in agar (pre-incubation)DURATION- Exposure duration: Experiment 1. All of the plates were incubated at 37 ± 3 ºC for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). A number of manual counts were performed, predominantly due to colonies spreading, light background contamination and artefacts on the plates, thus distorting the actual plate count.Experiment 2. 0.1 mL of the appropriate bacterial strain culture, 0.5 mL of phosphate buffer OR S9-mix (as appropriate) and 0.1 mL of the test item formulation, vehicle or 0.1 mL of appropriate positive control were incubated at 37 ± 3 ºC for 20 minutes (with shaking) prior to addition of 2 mL of molten amino-acid supplemented media Subsequently, the procedure for incubation and duration was the same as in Experiment 1.NUMBER OF REPLICATIONS: 3DETERMINATION OF CYTOTOXICITY- Method: relative total growth
- Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:1. A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).2. A reproducible increase at one or more concentrations.3. Biological relevance against in-house historical control ranges.4. Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).5. Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out of historical range response (Cariello and Piegorsch, 1996)).A test item is considered non-mutagenic (negative) in the test system if the above criteria are not met.In instances of data prohibiting definitive judgement about test item activity are reported as equivocal.
- Statistics:
- Statistical methods (Mahon, et al.); as recommended by the UKEMS Subcommittee on Guidelines for Mutagenicity Testing, Report - Part III (1989).
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- maximum recommended dose level of 5000 µg/plate using preincubation method (EXP2) only
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- maximum recommended dose level of 5000 µg/plate using preincubation method (EXP2) only
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Under the conditions of this study the test material was considered to be non-mutagenic in the presence and absence of S9 activation.
- Executive summary:
The study was performed to the requirements of OECD Guideline 471, EU Method B13/14, US EPA OCSPP 870.5100 and Japanese guidelines for bacterial mutagenicity testing under GLP, to evaluate the potential mutagenicity of the test substance in a bacterial reverse mutation assay using S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2uvrA- in both the presence and absence of S-9 mix. The test strains were treated with the test substance using both the Ames plate incorporation and pre incubation methods at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). The dose range for Experiment 1 was predetermined and was 1.5 to 5000 µg/plate. The experiment was repeated on a separate day (pre-incubation method) using fresh cultures of the bacterial strains and fresh test item formulations. Eight test item dose levels were again selected in Experiment 2 in order to achieve both a minimum of four non-toxic dose levels and the toxic limit of the test item following the change in test methodology. The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated. The maximum dose level of the test item in the first experiment was selected as the maximum recommended dose level of 5000 μg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test (plate incorporation method), although small reductions in revertant colony frequency were noted to several of the tester strains at the upper test item dose levels. These results were not indicative of toxicity sufficiently severe enough to prevent the test item being tested up to the maximum recommended dose level of 5000 μg/plate in the second mutation test. The test item did induce a visible reduction in the growth of the bacterial background lawns and/or small reductions in revertant colony frequency to the majority of tester strains in the second mutation test (pre-incubation method) at 5000 μg/plate in both the presence and absence of metabolic activation (S9-mix). No test item precipitate was observed on the plates at any of the doses tested in either the presence or absence of S9-mix.There were no toxicologically significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation in Experiment 1 (plate incorporation method). Similarly, no significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation in Experiment 2 (pre-incubation method). Small, statistically significant increases in revertant colony frequency were observed in the first mutation test at 1500 μg/plate (TA100) and 500 μg/plate (TA98) in the absence of S9-mix only. These increases were considered to be of no biological relevance because there was no evidence of a dose-response relationship or reproducibility. Furthermore, the individual revertant counts at the statistically significant dose levels were within the in-house historical untreated/vehicle control range for each tester strain and the maximum fold increase was only 1.9 times the concurrent vehicle controls. It was concluded that, under the conditions of this assay, the test substance gave a negative, i.e. non-mutagenic response in S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2uvrA- in the presence and absence of S-9 mix.
Reference
Table 1 : Test Results: Experiment 1 with and without metabolic activation and results of concurrent positive controls
S9-Mix (-) | Dose Level Per Plate | Number of revertants (mean) +/- SD | |||||||||
Base-pair substitution strains | Frameshift strains | ||||||||||
TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |||||||
Solvent Control (DMSO) | 83 78 75 | (79) 4.0# | 16 11 7 | (11) 4.5 | 27 20 19 | (22) 4.4 | 20 12 13 | (15) 4.4 | 15 11 17 | (14) 3.1 | |
1.5 µg | 95 75 91 | (87) 10.6 | 14 11 14 | (13) 1.7 | 17 32 28 | (26) 7.8 | 21 21 11 | (18) 5.8 | 16 14 10 | (13) 3.1 | |
5 µg | 75 82 68 | (75) 7.0 | 12 11 9 | (11) 1.5 | 21 21 15 | (19) 3.5 | 13 21 20 | (18) 4.4 | 14 11 12 | (12) 1.5 | |
15 µg | 95 100 76 | (90) 12.7 | 17 11 13 | (14) 3.1 | 20 21 15 | (19) 3.2 | 20 32 27 | (26) 6.0 | 7 9 6 | (7) 1.5 | |
50 µg | 82 80 91 | (84) 5.9 | 12 10 18 | (13) 4.2 | 21 23 12 | (19) 5.9 | 27 12 27 | (22) 8.7 | 8 14 18 | (13) 5.0 | |
150 µg | 94 94 98 | (95) 2.3 | 23 13 12 | (16) 6.1 | 20 20 23 | (21) 1.7 | 20 24 17 | (20) 3.5 | 6 17 7 | (10) 6.1 | |
500 µg | 80 99 92 | (90) 9.6 | 12 12 10 | (11) 1.2 | 19 21 19 | (20) 1.2 | 33 24 29 | * (29) 4.5 | 11 7 11 | (10) 2.3 | |
1500 µg | 96 88 106 | * (97) 9.0 | 7 7 7 | (7) 0.0 | 19 20 19 | (19) 0.6 | 29 24 11 | (21) 9.3 | 12 11 8 | (10) 2.1 | |
5000 µg | 83 80 72 | (78) 5.7 | 8 6 7 | (7) 1.0 | 33 19 25 | (26) 7.0 | 13 12 20 | (15) 4.4 | 5 4 5 | (5) 0.6 | |
Positive controls S9-Mix (-) | Name Dose Level No. of Revertants | ENNG | ENNG | ENNG | 4NQO | 9AA | |||||
3 µg | 5 µg | 2 µg | 0.2 µg | 80 µg | |||||||
597 621 637 | (618) 20.1 | 200 319 270 | (263) 59.8 | 1200 1195 1155 | (1183) 24.7 | 192 158 200 | (183) 22.3 | 1219 1070 1232 | (1174) 90.0 | ||
S9-Mix (+) | Dose Level Per Plate | Number of revertants (mean) +/- SD | |||||||||
Base-pair substitution strains | Frameshift strains | ||||||||||
TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |||||||
Solvent Control (DMSO) | 102 114 114 | (110) 6.9# | 15 16 16 | (16) 0.6 | 24 24 33 | (27) 5.2 | 23 22 19 | (21) 2.1 | 15 19 17 | (17) 2.0 | |
1.5 µg | 86 91 100 | (92) 7.1 | 13 19 11 | (14) 4.2 | 27 20 35 | (27) 7.5 | 23 24 24 | (24) 0.6 | 11 16 19 | (15) 4.0 | |
5 µg | 107 130 102 | (113) 14.9 | 12 7 7 | (9) 2.9 | 25 35 29 | (30) 5.0 | 24 27 16 | (22) 5.7 | 15 16 17 | (16) 1.0 | |
15 µg | 120 106 94 | (107) 13.0 | 12 10 11 | (11) 1.0 | 27 32 29 | (29) 2.5 | 28 21 20 | (23) 4.4 | 15 9 12 | (12) 3.0 | |
50 µg | 94 84 115 | (98) 15.8 | 6 14 8 | (9) 4.2 | 29 33 20 | (27) 6.7 | 24 20 15 | (20) 4.5 | 6 13 15 | (11) 4.7 | |
150 µg | 98 90 114 | (101) 12.2 | 8 13 7 | (9) 3.2 | 28 36 23 | (29) 6.6 | 18 18 25 | (20) 4.0 | 14 17 15 | (15) 1.5 | |
500 µg | 83 79 80 | (81) 2.1 | 9 9 10 | (9) 0.6 | 28 25 19 | (24) 4.6 | 22 26 22 | (23) 2.3 | 9 16 11 | (12) 3.6 | |
1500 µg | 119 108 104 | (110) 7.8 | 6 6 5 | (6) 0.6 | 16 20 16 | (17) 2.3 | 19 20 12 | (17) 4.4 | 11 8 5 | (8) 3.0 | |
5000 µg | 103 98 79 | (93) 12.7 | 5 6 ! | (6) 0.7 | 21 16 20 | (19) 2.6 | 18 24 15 | (19) 4.6 | 9 13 8 | (10) 2.6 | |
Positive controls S9-Mix (+) | Name Dose Level No. of Revertants | 2AA | 2AA | 2AA | BP | 2AA | |||||
1 µg | 2 µg | 10 µg | 5 µg | 2 µg | |||||||
593 600 591 | (595) 4.7 | 246 226 246 | (239) 11.5 | 270 297 346 | (304) 38.5 | 211 195 226 | (211) 15.5 | 450 438 385 | (424) 34.6 |
Table 2 : Test Results: Experiment 2 with and without metabolic activation and results of concurrent positive controls
S9-Mix (-) | Dose Level Per Plate | Number of revertants (mean) +/- SD | |||||||||
Base-pair substitution strains | Frameshift strains | ||||||||||
TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |||||||
Solvent Control (DMSO) | 99 118 131 | (116) 16.1# | 11 15 20 | (15) 4.5 | 21 23 33 | (26) 6.4 | 12 20 19 | (17) 4.4 | 15 12 13 | (13) 1.5 | |
1.5 µg | 87 132 83 | (101) 27.2 | 13 12 19 | (15) 3.8 | 28 32 20 | (27) 6.1 | 15 23 20 | (19) 4.0 | 13 17 15 | (15) 2.0 | |
5 µg | 94 112 108 | (105) 9.5 | 17 21 20 | (19) 2.1 | 17 28 15 | (20) 7.0 | 16 13 17 | (15) 2.1 | 13 16 11 | (13) 2.5 | |
15 µg | 104 102 74 | (93) 16.8 | 13 23 13 | (16) 5.8 | 23 24 27 | (25) 2.1 | 12 25 15 | (17) 6.8 | 12 9 12 | (11) 1.7 | |
50 µg | 114 91 102 | (102) 11.5 | 16 13 15 | (15) 1.5 | 24 28 23 | (25) 2.6 | 27 20 17 | (21) 5.1 | 8 11 12 | (10) 2.1 | |
150 µg | 68 100 92 | (87) 16.7 | 16 15 13 | (15) 1.5 | 23 23 21 | (22) 1.2 | 25 17 20 | (21) 4.0 | 12 12 9 | (11) 1.7 | |
500 µg | 82 82 91 | (85) 5.2 | 17 16 16 | (16) 0.6 | 21 17 17 | (18) 2.3 | 17 20 13 | (17) 3.5 | 13 7 12 | (11) 3.2 | |
1500 µg | 99 108 87 | (98) 10.5 | 9 13 9 | (10) 2.3 | 19 20 19 | (19) 0.6 | 12 13 13 | (13) 0.6 | 4 7 5 | (5) 1.5 | |
5000 µg | 69 S 65 S 65 S | (66) 2.3 | 8 S 7 S 7 S | (7) 0.6 | 7 S 15 S 9 S | (10) 4.2 | 11 S 8 S 9 S | (9) 1.5 | 3 S 2 S 2 S | (2) 0.6 | |
Positive controls S9-Mix (-) | Name Dose Level No. of Revertants | ENNG | ENNG | ENNG | 4NQO | 9AA | |||||
3 µg | 5 µg | 2 µg | 0.2 µg | 80 µg | |||||||
674 683 605 | (654) 42.7 | 500 279 497 | (425) 126.7 | 1026 1111 994 | (1044) 60.5 | 293 553 338 | (395) 139.0 | 1029 1004 1024 | (1019) 13.2 | ||
S9-Mix (+) | Dose Level Per Plate | Number of revertants (mean) +/- SD | |||||||||
Base-pair substitution strains | Frameshift strains | ||||||||||
TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |||||||
Solvent Control (DMSO) | 116 132 122 | (123) 8.1# | 16 19 16 | (17) 1.7 | 32 45 24 | (34) 10.6 | 20 23 17 | (20) 3.0 | 11 11 16 | (13) 2.9 | |
1.5 µg | 134 128 110 | (124) 12.5 | 15 15 13 | (14) 1.2 | 32 39 28 | (33) 5.6 | 26 14 18 | (19) 6.1 | 15 12 11 | (13) 2.1 | |
5 µg | 130 128 136 | (131) 4.2 | 15 12 17 | (15) 2.5 | 32 49 44 | (42) 8.7 | 23 15 18 | (19) 4.0 | 11 12 13 | (12) 1.0 | |
15 µg | 119 124 104 | (116) 10.4 | 11 9 16 | (12) 3.6 | 32 29 45 | (35) 8.5 | 20 19 22 | (20) 1.5 | 11 12 10 | (11) 1.0 | |
50 µg | 120 112 112 | (115) 4.6 | 21 17 16 | (18) 2.6 | 24 32 32 | (29) 4.6 | 17 19 18 | (18) 1.0 | 9 11 12 | (11) 1.5 | |
150 µg | 115 132 114 | (120) 10.1 | 13 11 23 | (16) 6.4 | 24 25 24 | (24) 0.6 | 22 22 22 | (22) 0.0 | 11 16 11 | (13) 2.9 | |
500 µg | 120 124 106 | (117) 9.5 | 19 13 15 | (16) 3.1 | 28 33 44 | (35) 8.2 | 13 15 17 | (15) 2.0 | 7 11 16 | (11) 4.5 | |
1500 µg | 111 106 112 | (110) 3.2 | 10 8 7 | (8) 1.5 | 25 19 28 | (24) 4.6 | 21 20 13 | (18) 4.4 | 7 5 9 | (7) 2.0 | |
5000 µg | 88 S 79 S 64 S | (77) 12.1 | 6 S 5 S 6 S | (6) 0.6 | 16 19 11 | (15) 4.0 | 8 S 9 S 7 S | (8) 1.0 | 3 S 5 S 5 S | (4) 1.2 | |
Positive controls S9-Mix (+) | Name Dose Level No. of Revertants | 2AA | 2AA | 2AA | BP | 2AA | |||||
1 µg | 2 µg | 10 µg | 5 µg | 2 µg | |||||||
436 442 418 | (432) 12.5 | 154 163 124 | (147) 20.4 | 235 223 253 | (237) 15.1 | 557 446 378 | (460) 90.4 | 218 200 186 | (201) 16.0 |
ENNG : N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO : 4-Nitroquinoline-1-oxide
9AA : 9-Aminoacridine
BP : Benzo(a)pyrene
2AA : 2-Aminoanthracene
P : Test item precipitate
!: No growth at all, therefore plate considered misdosed
S: Sparse bacterial background lawn
V : Very weak bacterial background lawn
# : Standard deviation
Table 3. Spontaneous Mutation Rates (Concurrent Negative Controls): Experiment 1 and 2, respectively
Number of revertants (mean number of colonies per plate) | |||||||||
Base-pair substitution type | Frameshift type | ||||||||
TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |||||
68 |
| 16 |
| 25 |
| 25 |
| 12 |
|
79 | (78) | 10 | (14) | 21 | (22) | 32 | (26) | 5 | (9) |
86 |
| 16 |
| 20 |
| 21 |
| 11 |
|
Number of revertants (mean number of colonies per plate) | |||||||||
Base-pair substitution type | Frameshift type | ||||||||
TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |||||
138 |
| 13 |
| 36 |
| 20 |
| 16 |
|
120 | (124) | 16 | (17) | 23 | (27) | 20 | (19) | 13 | (13) |
114 |
| 23 |
| 21 |
| 17 |
| 11 |
|
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
OECD TG 471, 2016 - The study was performed to the requirements of OECD Guideline 471, EU Method B13/14, US EPA OCSPP 870.5100 and Japanese guidelines for bacterial mutagenicity testing under GLP, to evaluate the potential mutagenicity of the test substance in a bacterial reverse mutation assay using S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2uvrA- in both the presence and absence of S-9 mix. The test strains were treated with the test substance using both the Ames plate incorporation and pre incubation methods at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). The dose range for Experiment 1 was predetermined and was 1.5 to 5000 µg/plate. The experiment was repeated on a separate day (pre-incubation method) using fresh cultures of the bacterial strains and fresh test item formulations. Eight test item dose levels were again selected in Experiment 2 in order to achieve both a minimum of four non-toxic dose levels and the toxic limit of the test item following the change in test methodology. The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated. The maximum dose level of the test item in the first experiment was selected as the maximum recommended dose level of 5000 μg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test (plate incorporation method), although small reductions in revertant colony frequency were noted to several of the tester strains at the upper test item dose levels. These results were not indicative of toxicity sufficiently severe enough to prevent the test item being tested up to the maximum recommended dose level of 5000 μg/plate in the second mutation test. The test item did induce a visible reduction in the growth of the bacterial background lawns and/or small reductions in revertant colony frequency to the majority of tester strains in the second mutation test (pre-incubation method) at 5000 μg/plate in both the presence and absence of metabolic activation (S9-mix). No test item precipitate was observed on the plates at any of the doses tested in either the presence or absence of S9-mix.There were no toxicologically significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation in Experiment 1 (plate incorporation method). Similarly, no significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation in Experiment 2 (pre-incubation method). Small, statistically significant increases in revertant colony frequency were observed in the first mutation test at 1500 μg/plate (TA100) and 500 μg/plate (TA98) in the absence of S9-mix only. These increases were considered to be of no biological relevance because there was no evidence of a dose-response relationship or reproducibility. Furthermore, the individual revertant counts at the statistically significant dose levels were within the in-house historical untreated/vehicle control range for each tester strain and the maximum fold increase was only 1.9 times the concurrent vehicle controls. It was concluded that, under the conditions of this assay, the test substance gave a negative, i.e. non-mutagenic response in S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2uvrA- in the presence and absence of S-9 mix.
Justification for selection of genetic toxicity
endpoint
Study selected is an in vitro study (Klimisch 1)
Short description of key information:
negative, in vitro bacterial reverse mutation (with and without S-9
activation), OECD TG 471, 2016
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
The substance does not meet classification criteria under Regulation (EC) No 1272/2008 for mutagenicity
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
